[ad_1]
Broder, C. C. & Wong, K. T. Henipaviruses. In Neurotropic Viral Infections: Volume 1: Neurotropic RNA Viruses (ed. Reiss C. S.). p. 45–83 (Springer International Publishing, Cham 2016).
Lamb, R. A. & Parks, G. D. Paramyxoviridae: the viruses and their replication. Fields Virology. 5, 1449–1496 (2007).
Amaya, M. & Broder, C. C. Vaccines to emerging viruses: Nipah and Hendra. Annu. Rev. Virol. 7, 447–73 (2020).
Marsh, G. A. et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog. 8, e1002836 (2012).
Drexler, J. F. et al. Henipavirus RNA in African Bats. PLoS ONE 4, e6367 (2009).
Wu, Z. et al. Novel Henipa-like virus, Mojiang Paramyxovirus, in rats, China, 2012. Emerg. Infect. Dis. 20, 1064–1066 (2014).
Lee, S. H. et al. Discovery and genetic characterization of novel paramyxoviruses related to the genus henipavirus in crocidura species in the Republic of Korea. Viruses 13, 2020 (2021).
Zhang, X.-A. et al. A zoonotic henipavirus in febrile patients in China. N. Engl. J. Med. 387, 470–472 (2022).
Halpin, K. et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am. J. Tropical Med. Hyg. 85, 946–951 (2011).
Bossart, K. N. et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 4, 146ra07 (2012).
Geisbert, T. W. et al. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. npj Vaccines 6, 23 (2021).
Mire, C. E. et al. A Recombinant Hendra Virus G Glycoprotein Subunit Vaccine Protects Nonhuman Primates against Hendra Virus Challenge. J. Virol. 88, 4624 (2014).
Pallister, J. A. et al. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol. J. 10, 237 (2013).
Pager, C. T., Craft, W. W. Jr, Patch, J. & Dutch, R. E. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. Virology 346, 251–257 (2006).
Pager, C. T. & Dutch, R. E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J. Virol. 79, 12714–12720 (2005).
Lee, B. & Akyol-Ataman, Z. Modes of Paramyxovirus fusion: a Henipavirus perspective. Trends Microbiol. 19, 389–399 (2011).
Lou, Z. et al. Crystal structures of Nipah and Hendra virus fusion core proteins. FEBS J. 273, 4538–4547 (2006).
Wong, J. J., Paterson, R. G., Lamb, R. A. & Jardetzky, T. S. Structure and stabilization of the Hendra virus F glycoprotein in its prefusion form. Proc. Natl Acad. Sci. USA 113, 1056–1061 (2016).
Xu, K. et al. Crystal structure of the pre-fusion Nipah virus fusion glycoprotein reveals a novel hexamer-of-trimers assembly. PLoS Pathog. 11, e1005322 (2015).
Lamb, R. A., Paterson, R. G. & Jardetzky, T. S. Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 344, 30–37 (2006).
Avanzato, V. A. et al. A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. Proc. Natl Acad. Sci. USA 116, 25057 (2019).
Dang, H. V. et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat. Struct. Mol. Biol. 26, 980–987 (2019).
Dang, H. V. et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat. Struct. Mol. Biol. 28, 426–434 (2021).
Mire, C. E. et al. A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal Nipah virus and Hendra virus infection. J. Infect. Dis. 221, S471–S9 (2020).
Isaacs, A. et al. Combinatorial F-G immunogens as Nipah and respiratory syncytial virus vaccine candidates. Viruses 13, 1942 (2021).
Loomis, R. J. et al. Structure-based design of Nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development. Front. Immunol. 11, 842 (2020).
Pedrera, M. et al. Bovine Herpesvirus-4-vectored delivery of Nipah virus glycoproteins enhances T cell immunogenicity in pigs. Vaccines 8, 115 (2020).
Young, A. et al. A platform technology for generating subunit vaccines against diverse viral pathogens. Front. Immunol. 13, 963023 (2022).
Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–94.e9 (2020).
Ferreira, R.-C. et al. Structural rearrangements maintain the glycan shield of an HIV-1 envelope trimer after the loss of a glycan. Sci. Rep. 8, 15031 (2018).
Colgrave, M. L. et al. Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. Glycobiology 22, 572–584 (2012).
Moll, M., Kaufmann, A. & Maisner, A. Influence of N-glycans on processing and biological activity of the nipah virus fusion protein. J. Virol. 78, 7274–7278 (2004).
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2020).
Leroux-Roels I. et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J. Infect. Dis. 227, 761–772 (2023).
McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).
Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501 (2020).
Watterson, D. et al. Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin. Transl. Immunol. 10, e1269 (2021).
Chan, Y.-P. et al. Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins. J. Virol. 86, 11457–11471 (2012).
Aguilar, H. C. et al. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 80, 4878–4889 (2006).
Madera, S. et al. Discovery and genomic characterization of a Novel Henipavirus, Angavokely virus, from fruit bats in Madagascar. J. Virol. 96, e0092122 (2022).
Rissanen, I. et al. Idiosyncratic Mòjiāng virus attachment glycoprotein directs a host-cell entry pathway distinct from genetically related henipaviruses. Nat. Commun. 8, 16060 (2017).
Ducatez, M. F. et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc. Natl Acad. Sci. USA 108, 349–354 (2011).
Kothe, D. L. et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352, 438–449 (2006).
Pernet, O. et al. Evidence for henipavirus spillover into human populations in Africa. Nat. Commun. 5, 5342 (2014).
Al Qaraghuli, M. M. & Ferro, V. A. Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens. J. Mol. Recognit. 30, e2592 (2017).
Desmyter, A., Spinelli, S., Roussel, A. & Cambillau, C. Camelid nanobodies: killing two birds with one stone. Curr. Opin. Struct. Biol. 32, 1–8 (2015).
Wu, Y., Jiang, S. & Ying, T. Single-domain antibodies as therapeutics against human viral diseases. Front. Immunol. 8, 1802 (2017).
Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439–443 (2013).
Fischer, K., Topallar, S., Kraatz, F., Groschup, M. H. & Diederich, S. The role of N-linked glycosylation in proteolytic processing and cell surface transport of the Cedar virus fusion protein. Virol. J. 19, 136 (2022).
Biering, S. B. et al. N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J. Virol. 86, 11991–12002 (2012).
Bradel-Tretheway, B. G., Liu, Q., Stone, J. A., McInally, S. & Aguilar, H. C. Novel functions of Hendra virus G N-glycans and comparisons to Nipah virus. J. Virol. 89, 7235–7247 (2015).
Casalino, L. et al. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. ACS Cent. Sci. 6, 1722–1734 (2020).
Chu, F. et al. Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein. Virus Res. 174, 137–147 (2013).
Panda, A., Elankumaran, S., Krishnamurthy, S., Huang, Z. & Samal, S. K. Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus. J. Virol. 78, 4965–4975 (2004).
Sawatsky, B. & von Messling, V. Canine distemper viruses expressing a hemagglutinin without N-glycans lose virulence but retain immunosuppression. J. Virol. 84, 2753–2761 (2010).
Jones, M. L. et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J. Immunol. Methods 354, 85–90 (2010).
Yonekura, K., Maki-Yonekura, S., Naitow, H., Hamaguchi, T. & Takaba, K. Machine learning-based real-time object locator/evaluator for cryo-EM data collection. Commun. Biol. 4, 1044 (2021).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Jamali, K., Kimanius, D. & Scheres, S. ModelAngelo: automated model building in Cryo-EM maps. Preprint at https://arxiv.org/abs/2210.00006 (2022).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486–501 (2010).
Croll, T. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Sect. D 74, 519–30 (2018).
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D 75, 861–77 (2019).
Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Pegg, C. L., Zacchi, L. F., Recinos, D. R., Howard, C. B. & Schulz, B. L. Identification of novel glycosylation events on human serum-derived factor IX. Glycoconj. J. 37, 471–83 (2020).
Baba, T. et al. Localization of multiple O-linked glycans exhibited in isomeric glycopeptides by hot electron capture dissociation. J. Proteome Res. 21, 2462–71 (2022).
Chernushevich, I. V., Merenbloom, S. I., Liu, S. & Bloomfield, N. A W-geometry ortho-TOF MS with high resolution and up to 100% duty cycle for MS/MS. J. Am. Soc. Mass Spectrom. 28, 2143–50 (2017).
Loboda, A. V. & Chernushevich, I. V. A novel ion trap that enables high duty cycle and wide m/z range on an orthogonal injection TOF mass spectrometer. J. Am. Soc. Mass Spectrom. 20, 1342–1348 (2009).
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–d52 (2022).
|
Sources 2/ https://www.nature.com/articles/s41467-023-39278-8 The mention sources can contact us to remove/changing this article |
[ad_2]